Pharmaceutical compositions of bactericidal/permeability increas

Details Pharmaceutical compositions of bactericidal/permeability increas Pharmaceutical compositions of bactericidal/permeability increas

1999-05-17

2000-05-23

Sayala, Chhaya D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 530350, A61K 3514

Patent

active

06066620&

ABSTRACT:
Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.

REFERENCES:
patent: 3839314 (1974-10-01), Fekete et al.
patent: 4478829 (1984-10-01), Landaburu et al.
patent: 4719239 (1988-01-01), Muller et al.
patent: 4933179 (1990-06-01), ALlison et al.
patent: 4997664 (1991-03-01), Williams
patent: 5030448 (1991-07-01), Hunter
patent: 5037664 (1991-08-01), Shaked et al.
patent: 5039520 (1991-08-01), Hunter
patent: 5041288 (1991-08-01), Hunter
patent: 5071649 (1991-12-01), Hunter
patent: 5089274 (1992-02-01), Marra et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5118528 (1992-06-01), Fessi et al.
patent: 5118794 (1992-06-01), Grangeorge et al.
patent: 5133908 (1992-07-01), Stainmesse et al.
patent: 5152979 (1992-10-01), Hunter
patent: 5171739 (1992-12-01), Scott
patent: 5182106 (1993-01-01), Mezrow et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234683 (1993-08-01), Hunter et al.
patent: 5234908 (1993-08-01), Szabo et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5439807 (1995-08-01), Grinna
FDA, Division of Drug Information Resources, "Inactive Ingredient Guide" including list of "Currently Marketed Injectable Products," (1991).
FDA review and basis for approval of OB-NDA-86-0909 on FLUOSOL.RTM. (20% Intravascular Perflorochemical Emulsion), The Green Cross Corp. (1989).
Gazzano-Santoro, et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," Infection and Immunity, vol. 60, 4754-4761, (Nov., 1992).
Genentech, Inc., "A Tissue Plasminogen Activator," Product Information (1987).
Gray, et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," The Journal of Biological Chemistry, vol. 264, No. 16, 9505-9509 (Jun. 5, 1989).
The Green Cross Corporation, "Peruflorochemical Blood Substitutes," Technical Info. Series Nos. 5 & 7 (1978 and 1981).
Henson, et al., "The Surface Coagulation of Proteins During Shaking," J. Colloid & Interface Sci., 32(1):162-165 (Jan. 1970).
ICI Americas, Inc., "ICI Americas Products For Cosmetics and Pharmaceuticals," Chapters 1-4, pp. 1-39 (1977).
ICI Americas, Inc., "The HLB System," Chapters 1-8, pp. 3-20 (1984).
Kaplan and Fraser, "Formation of Fibres from Protein Monolayers," Nature, 171(4352):559-560 (Mar. 28, 1953).
Krantz, et al., "Sugar Alcohols," Bulletin of School of Medicine, U. of MD, 36:48-56 (1951).
Levine, et al., "The Use of Surface Tension Measurements in the Design of Antibody-Based Product Formulations," J. Parenteral Sci. & Tech., 45(3):160-165 (May-Jun. 1991).
MacRitchie, "Proteins at Interfaces," Adv. Protein Chem., 32:283-326 (1978).
Neugebauer, "A Guide to the Properties and Uses of Detergents in Biology and Biochemistry," Calbiochem.RTM. Brand Chemicals, Hoechst Celanese Corp. (1987).
Ooi, et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils," J. Exp. Med., vol. 174, 649-655 (Sep., 1991).
Ortho Pharmaceutical Corporation, "Orthocolone OKT-3," Product Information Package Insert (1986).
The U.S. Pharmacopeia USPXXII, pp. 1763, 1857, and NFXVII, pp. 1960-1, 1967-8.
Wang, et al., "Parenteral Formulations of Proteins and Peptides: Stability and Stabilzers," J. Parenteral Sci. Tech., 42(Supp. 25):S4-526 (1988).
Weiss, et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," Blood, vol. 69, No. 2, 652-659 (Feb., 1987).
Weiss, et al., "Resistance to Gram-negative Bacteria to Purified Bactericidal Leukocyte Proteins", J. Clin. Invest., 65:619-628 (Mar., 1980).
Wyandotte Chemicals Corporation, "Information on Applications of Pluronics," pp. 1-13 (Mar. 1, 1952).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions of bactericidal/permeability increas does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions of bactericidal/permeability increas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of bactericidal/permeability increas will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1837153